Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592833 | SCV000708502 | uncertain significance | not provided | 2017-05-19 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002483647 | SCV002777966 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2021-11-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003302922 | SCV003999498 | uncertain significance | Cardiovascular phenotype | 2023-04-05 | criteria provided, single submitter | clinical testing | The c.54657_54662dupCATCGT variant (also known as p.I18220_V18221dup), located in coding exon 153 of the TTN gene, results from an in-frame duplication of CATCGT at nucleotide positions 54657 to 54662. This results in the duplication of 2 extra residues (IV) between codons 18220 and 18221. This amino acid region is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |